[2]First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. [3] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) [4]
通常情况下,SMARCA4缺失型NSCLC的诊断,主要依据免疫组化染色检测SMARCA4(BRG1)蛋白表达缺失情况来确定[1]。本病例中,患者经NGS检测出EML4-ALK基因融合,并经免疫组化检测发现BRG1阴性,最终被诊断为SMARCA4缺失伴EML4-ALK基因融合IV期NSCLC。考虑到SMARCA4缺失型NSCLC的高侵袭性以及ALK-TKI恩沙替尼一线治疗EML4-ALK基因融合...
Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316). 2025 ASCO. 8015 [2] van der Wel JWT, et al. Novel strategies ...
8. Solomon BJ, et al. Updated Efficacy and Safety From the Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)[J].2022 AA...
ALK阳性非小细胞肺癌(NSCLC)发生率约为5%-7%,主要分为融合、点突变、扩增突变三种形式,其中ALK融合是ALK+的NSCLC致癌的主要驱动因素,在NSCLC中,以EML4-ALK融合突变为主。EML4-ALK融合有不同的融合亚型,其中以V1和V3a/3b亚型最为常见;ALK的点突变和扩增突变相对少见
ALK+=positive for the biomarker called anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer. Important Safety Information & Indications Who is ALECENSA for? ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anapl...
Conclusions: The findings, from a representative population of ALK-positive patients, provide new information on the significant disparities in the treatment that patients receive. This health inequality is likely to have a detrimental effect on the survival outcomes for some of these patients. It ...
Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.
Alectinib continued to show significantly prolonged PFS compared with crizotinib in patients with treatment-naive ALK-positive NSCLC (HR 0.43, 95% CI 0.32–0.58; median 34.8 versus 10.9 months, respectively), supporting the current recommendation by multiple national treatment guidelines of using a ...
[2]Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020; 31:1056. ...